Hemogenyx Pharmaceuticals (LSE:HEMO) Net Issuance of Preferred Stock : £0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Hemogenyx Pharmaceuticals's net issuance of preferred for the six months ended in Dec. 2023 was £0.00 Mil. The number is 0, which means that Hemogenyx Pharmaceuticals has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Hemogenyx Pharmaceuticals's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Hemogenyx Pharmaceuticals Net Issuance of Preferred Stock Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Net Issuance of Preferred Stock Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial												-	-	-	-	-

Hemogenyx Pharmaceuticals Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Hemogenyx Pharmaceuticals Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines